Advanced search
Publication Cover
Cancer Investigation Volume 28, 2010 - Issue 3
Submit an article Journal homepage
999
Views
6
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

Single Agent Vinflunine in the Salvage Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Trial of the Sarah Cannon Research Consortium

John D. HainsworthSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
,
Anthony A. MeluchSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
,
Cassie M. LaneSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
,
David R. SpigelSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
,
Howard A. Burris IIISarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
,
Jitendra G. GandhiSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
,
Edward J. CraneSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
,
Michael A. StipanovSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
&
F. Anthony GrecoSarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee, USA, Associates in Oncology/Hematology, Chattanooga, Tennessee, USA, Oncology Hematology Care, Cincinnati, Ohio, USA, Chattanooga Oncology and Hematology Associates, Chattanooga, Tennessee, USA.
 show all
Pages 275-279 | Published online: 26 Oct 2009

REFERENCES

  • Petrylak, D.P.; Tangen, C.M.; Hussain, M.N.A. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351, 1513–1520.
  • Tannock, I.F.; de Wit, R.; Berry, W.R. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351, 1502–1512.
  • Hill, B.T.; Flebig, H.H.; Waud, W.R. Superior in vivo experimental antitumour activity of vinflunine relative to vinorelbine in a panel of human tumour xenografts. Eur J Cancer 1999, 35, 512–520.
  • Culine, S.; Theodore, C.; DeSantis, M. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006, 94, 1395–1414.
  • Peacock, N.W.; Spigel, D.R.; Mainwaring, M.G. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2 + patients) as first-line treatment in metastatic breast cancer. J Clin Oncol 2007, 25, 42s (Abstract #1043).
  • Krzakowski, M.; Douillard, J.; Ramlau, R. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer previously treated with a platinum-containing regimen. J Clin Oncol 2007, 25, 387s (Abstract #7511).
  • Bubley, G.C.; Carducci, M.; Dahut, W. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999, 17, 3461–3467.
  • Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92, 205–216.
  • Kaplan, E.L.; Meier, P.; Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53, 457–481.
  • Dexeus, F.; Logothetis, C.J.; Samuels, M.L. Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer. Cancer Treat Rep 1985, 69, 885–886.
  • Hudes, G.; Einhorn, L.; Ross, E. Vinblastine versus vinplastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase II trial. J Clin Oncol 1999, 17, 3160–3166.
  • Caty, A.; Oudard, S.; Humblet, Y. Phase II study of vinorelbine in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 1997, 16, 311a–
  • Carles, J.; Domenech, M.; Gelabert-Mas, A. Phase II study of estramustine and vinorelbine in hormone-refractory prostate carcinoma patients. Acta Oncologica 1998, 37, 187–191.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.